Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA binding motif protein 22 pseudogene 6 (RBM22P6) is a non-coding pseudogene in humans[2][4]. It is a homologous DNA sequence to the protein-coding RNA binding motif protein 22 (RBM22), which is involved in pre-mRNA splicing as part of the spliceosome complex[1][6]. Pseudogenes like RBM22P6 are remnants of well-conserved protein-coding genes that have accumulated mutations rendering them incapable of producing functional proteins[5]. RBM22P6 is not known to play a direct biological or pathological role, nor is it considered a drug target, biomarker, or source of safety concern. It is included in genomic databases for completeness, but its transcription and functional relevance are effectively null; any information linking it to disease or therapeutic applications would be an error or misunderstanding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA binding motif protein 22 pseudogene 6 (RBM22P6).